Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with no effective treatments or known biomarkers for definitive diagnosis, substantiating the need for early detection of AD and early intervention. This project employs Magnetic Resonance Spectroscopy (MRS) to measure changes in neurometabolites as compared to behavioural measures of cognitive function, in a transgenic rat model of AD under treatment conditions. Preliminary results suggest that changes in metabolite levels are present before the onset of cognitive impairment, and between treatment and control groups, with some of these changes being sexually dimorphic.
This abstract and the presentation materials are available to members only; a login is required.